2011 Proved to be quite a year for medical breakthroughs, particularly the cervical cancer vaccine that has raised a lot of hope in women who have a history of cancer in their families. Breast cancer vaccines have been in the spotlight again for a vaccine medical trial, helmed by the American military, set to start early 2012.
The trial drug is called NeuVax and was developed to prohibit reoccurrence of cancer in survivors who are in remission. The vaccine is a combination of an immune system stimulant combined with E-75 peptide with the HER2/neu protein, designed to drive immune system attacks on HER-2 driven cancers. HER-2 cancer tests are positive for the human epidermal growth factor receptor 2 (HER2) which is a protein that encourages the growth of cancer cells. The breast cancer vaccine was developed to combat the protein.
The medical distribution for earlier trials on patients have shown successful signs of combating the recurrence of breast cancer. This is amazing news for anyone who has been through the battle of breast cancer. Developed by the Cancer Vaccine Development Program at San Antonia Military Medical Centre, Army colonel, Dr George Peoples confirmed that they have conducted several trials of the vaccine combined with Herceptin – breast cancer drug developed by Genentech – and the results have been excellent, with a recurrence rate of zero.
Hopefully once the trials prove that the breast cancer vaccine can successfully inhibit the recurrence of breast cancer, healthcare transport will be running back and forth for a while because every survivor may want to get their hands on this drug.